drugset / Trial / NCT00203424
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
Phase 2
Completed
23 enrolled
Translational Oncology Research International
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
Timeline
- Start
- 2006-01
- Primary completion
- 2009-02
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Erlotinib | Small molecule | — | — |